International Journal of Peptides / 2011 / Article / Tab 1

Review Article

Use of Ghrelin as a Treatment for Inflammatory Bowel Disease: Mechanistic Considerations

Table 1

Levels of acyl and total ghrelin among IBD subjects and healthy controls.

Healthy controlsCD, activeCD, remissionUC, activeUC, remissionIBD, activeIBD,
remission

Acyl ghrelin

Ates et al. 2008 [51] 8 4 ± 1 4 1 1 0 ± 1 0 *** 7 5 ± 1 5 1 0 8 ± 1 1 *** 7 1 ± 1 3
Karmiris et al. 2006 [52] 1 4 . 8 ± 3 . 0 4 9 . 4 ± 4 . 2 ### 4 8 . 2 ± 4 . 2 ###

Total ghrelin

Peracchi et al. 2006 [53] 2 0 3 ± 8 1 . 1 3 2 3 . 6 ± 1 1 9 . 2 , # # # 2 1 7 . 4 ± 6 4 . 9
Nishi et al. 2005 [54] 2 2 0 . 6 ± 9 8 . 8 NS 2 0 2 . 3 ± 8 6 . 4
Alexandridis et al. 2009 [55] 4 0 2 . 4 ± 4 6 2 . 6 1 4 8 . 2 ± 5 9 . 6 *

Statistical significance: active disease versus remission: * 𝑃 < 0 . 0 5 , *** 𝑃 < 0 . 0 0 1 ; active disease versus controls: ### 𝑃 < 0 . 0 0 1 ; NS: not significant.